...
首页> 外文期刊>European review for medical and pharmacological sciences. >CXCL13 inhibition induce the apoptosis of MDA-MB-231 breast cancer cells through blocking CXCR5/ERK signaling pathway
【24h】

CXCL13 inhibition induce the apoptosis of MDA-MB-231 breast cancer cells through blocking CXCR5/ERK signaling pathway

机译:CXCL13抑制通过阻断CXCR5 / ERK信号通路诱导MDA-MB-231乳腺癌细胞凋亡

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Treatment of the high-risk triple negative breast cancer (TNBC) is a critical clinical challenge. Here we aimed to explore a novel strategy for TNBC treatment by blocking the tumor-associated chemokine CXCL13 in the MDA-MB-231 TNBC cells. MATERIALS AND METHODS: MDA-MB-231 cells were treated with anti-CXCL13 antibodies (inhibition group), or phosphate-buffered saline (PBS) (control group), followed by determining the levels of interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-α) and transforming growth factor beta-1 (TGF-β1) with enzyme-linked immunosorbent assay (ELISA). The effects of CXCL13 inhibition on cell proliferation and apoptosis were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and flow cytometry, respectively. Quantitative Real Time-PCR (qRT-PCR) and Western blot were used to compare the levels of CXCL13, CXCR5, extracellular signal-regulated kinase (ERK). The levels of cyclin D1 and cleaved caspase-9 were detected by Western blot. RESULTS: The levels of IL-1, TNF-α and TGF-β1 in MDA-MB-231 cells treated with anti-CXCL13 antibodies were significantly downregulated (p0.05). Meanwhile, CXCL13 blockade decreased the cell proliferation and increased the apoptosis rate of MDA-MB-231 cells. The inhibition of CXCL13 led to marked reduction in CXCL13 and CXCR5 mRNA and an increase in ERK mRNA. The inhibition of CXCL13 resulted in the downregulation of CXCL13, CXCR5, p-ERK/ERK, cyclin D1 and upregulation of cleaved caspase-9 proteins. CONCLUSIONS: CXCL13 blockade effectively suppressed the proliferation of MDA-MB-231 cells by promoting cell apoptosis. This effect is presumably associated with the downregulation of CXCL13 and suppression of the CXCR5/ERK signaling pathway.
机译:目的:治疗高危三阴性乳腺癌(TNBC)是一项关键的临床挑战。在这里,我们旨在探索通过阻断MDA-MB-231 TNBC细胞中与肿瘤相关的趋化因子CXCL13来治疗TNBC的新策略。材料与方法:用抗CXCL13抗体(抑制组)或磷酸盐缓冲液(PBS)(对照组)处理MDA-MB-231细胞,然后测定白介素1(IL-1)水平,酶联免疫吸附法(ELISA)检测肿瘤坏死因子-α(TNF-α)和转化生长因子β-1(TGF-β1)。分别通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)测定和流式细胞术评估了CXCL13抑制对细胞增殖和凋亡的影响。实时荧光定量PCR(qRT-PCR)和蛋白质印迹用于比较CXCL13,CXCR5,细胞外信号调节激酶(ERK)的水平。通过Western印迹检测细胞周期蛋白D1和裂解的caspase-9的水平。结果:用抗CXCL13抗体处理的MDA-MB-231细胞中IL-1,TNF-α和TGF-β1的水平显着下调(p <0.05)。同时,CXCL13阻断降低了MDA-MB-231细胞的增殖并提高了其凋亡率。 CXCL13的抑制导致CXCL13和CXCR5 mRNA的显着减少和ERK mRNA的增加。 CXCL13的抑制导致CXCL13,CXCR5,p-ERK / ERK,细胞周期蛋白D1的下调和裂解的caspase-9蛋白的上调。结论:CXCL13阻断通过促进细胞凋亡有效抑制MDA-MB-231细胞的增殖。据推测,这种作用与CXCL13的下调和CXCR5 / ERK信号通路的抑制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号